Article
PD-L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non-small cell lung cancer with uncommon EGFR mutations treated with first-line second-generation EGFR-tyrosine kinase inhibitors.
Cancer - 15 May 2026
Jin Hongping, Wang Yue, Zhang Yidan, Wu Yiqing, Liu Tengfei, Xu Jianlin, Chu Tianqing, Zhong Hua, Yang Huizhen, Zhong Runbo
Abstract excerpt
BACKGROUND: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are key first-line therapies for advanced non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, with risk stratification mainly based on EGFR mutation subtypes. Emerging evidence suggests programmed death-ligand 1 (PD-L1) expression may affect EGFR-TKI efficacy. This study compared associations of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.